Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer.

Cancer letters - 28 Aug 2011

Oshima Kazuteru, Naoi Yasuto, Kishi Kazuki, Nakamura Yukiko, Iwamoto Takashi, Shimazu Kenzo, Nakayama Takahiro, Kim Seung Jin, Baba Yosuke, Tamaki Yasuhiro, Noguchi Shinzaburo

Abstract excerpt

PURPOSE: The aim of this study was to determine whether TP53 mutation status (MS) can predict response of breast cancer to paclitaxel followed by 5-FU/epirubicin/cyclophosphamide (P-FEC). TP53 gene expression signature (GES) was also examined for its predictive capability of response to P-FEC since TP53 GES provides a more accurate measure of the functional configuration of TP53. METHODS: Tumor samples were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cluster Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Epirubicin

Share to Fluorouracil

Share to Immunohistochemistry

Share to Paclitaxel

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 21514041
DOI: 10.1016/j.canlet.2011.03.027

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer.PMID 21514041Read ↗

An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.Semantic proximity Read ↗

Transcriptional profiling reveals a subset of human breast tumors that retain wt <i>TP53</i> but display mutant p53-associated featuresSemantic proximity Read ↗

TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients.Semantic proximity Read ↗

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial.Semantic proximity Read ↗

Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.Semantic proximity Read ↗

p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.Semantic proximity Read ↗

Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers.Semantic proximity Read ↗

Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.Semantic proximity Read ↗

Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis.Semantic proximity Read ↗

Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trialSemantic proximity Read ↗

TP53 signature diagnostic system using multiplex reverse transcription-polymerase chain reaction system enables prediction of prognosis of breast cancer patients.Semantic proximity Read ↗

Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.